Dimensional Fund Advisors LP Has $215,000 Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Dimensional Fund Advisors LP increased its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 217.6% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 72,210 shares of the company’s stock after acquiring an additional 49,475 shares during the period. Dimensional Fund Advisors LP’s holdings in Trevi Therapeutics were worth $215,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Opaleye Management Inc. raised its position in Trevi Therapeutics by 4.3% in the 1st quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock valued at $9,125,000 after purchasing an additional 110,000 shares during the last quarter. Vanguard Group Inc. raised its position in Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after purchasing an additional 60,249 shares during the last quarter. Rosalind Advisors Inc. raised its position in Trevi Therapeutics by 50.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after purchasing an additional 465,561 shares during the last quarter. Propel Bio Management LLC bought a new position in Trevi Therapeutics in the 1st quarter valued at $897,000. Finally, Bank of New York Mellon Corp raised its position in Trevi Therapeutics by 38.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock valued at $532,000 after purchasing an additional 49,884 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Up 1.9 %

Shares of Trevi Therapeutics stock opened at $3.18 on Tuesday. Trevi Therapeutics, Inc. has a 12 month low of $0.97 and a 12 month high of $4.00. The stock has a market cap of $223.98 million, a PE ratio of -9.35 and a beta of 0.97. The business has a fifty day simple moving average of $3.05 and a 200 day simple moving average of $2.89.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same quarter in the prior year, the company posted ($0.07) earnings per share. Analysts expect that Trevi Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. HC Wainwright assumed coverage on Trevi Therapeutics in a research report on Friday, August 30th. They set a “buy” rating and a $6.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a research report on Friday, October 4th. EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Finally, B. Riley reaffirmed a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research note on Monday, October 7th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $7.43.

Insider Activity

In related news, CEO Jennifer L. Good sold 10,981 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $644,205.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Thomas Sciascia sold 18,660 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now owns 220,315 shares in the company, valued at approximately $608,069.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the sale, the chief executive officer now owns 213,313 shares in the company, valued at $644,205.26. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,355 shares of company stock worth $116,663 over the last three months. Corporate insiders own 24.37% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.